Seonix was founded by leading ophthalmologists and researchers who understand the impact of glaucoma vision loss on peoples’ lives. Building on many years of research, and access to some of the world’s largest glaucoma datasets, they identified thousands of genetic variants that increase an individual’s risk of glaucoma and developed this into a genetic risk score.
Seonix is now a growing company committed to bringing the benefits of improved genetic risk prediction information to eye health professionals, individuals, and researchers.
Our mission is to reduce blinding eye disease through the development of advanced techniques for clinical risk prediction.
Our leadership team
Seonix’s leadership comprises clinicians, researchers and industry experts who firmly believe there is a better way to identify individuals at risk of glaucoma so they can be diagnosed sooner.